Atlas Trials

Study of Oral Lucitanib (E-3810), a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, in Patients With Solid Tumors

Clinical trial NCT01283945 · COMPLETED

Trial details

NCT number
NCT01283945
Sponsor
Institut de Recherches Internationales Servier
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Solid Tumors
Start date
2010-07-01
Primary completion
2016-09-01
Enrollment
134

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.